Recombinant CA9 (Girentuximab Biosimilar) antibody

Catalog No. ABIN7538057

This Human Chimeric antibody specifically detects CA9 (Girentuximab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.

Quick Overview for Recombinant CA9 (Girentuximab Biosimilar) antibody (ABIN7538057)

Target: CA9 (Girentuximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human, Mouse

Clonality: Chimeric

Conjugate: This CA9 (Girentuximab Biosimilar) antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Grade: Research Grade

Product Details anti-CA9 (Girentuximab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Girentuximab Biosimilar - Anti-CA9 mAb - Research Grade

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Purity: > 85%

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS buffer PH7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for CA9 (Girentuximab Biosimilar)

Target: CA9 (Girentuximab Biosimilar)

Target Type: Biosimilar

Background: Recombinant chimeric antibody binding to human CA9. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.

CAS-No: 916138-87-9